Due to the limited efficacy of first-generation anti-androgens in complete blockage of androgen receptor activity, recently, four second-generation anti-androgens, including abiraterone acetate, enzalutamide, apalutamide, and darolutamide approved by the United States Food and Drug Administration, and considered standard of care for patients with advanced prostate cancer. This evidence concerns the gene AR and prostate carcinoma.